Related Experiment Video
Updated: May 15, 2025

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
IgA-type macroprolactin among 130 patients with macroprolactinemia
Masayuki Ishihara1, Naoki Hattori1, Norito Nishiyama1,2
1Department of Orthopedic Surgery, Kansai Medical University, Osaka, Japan.
IgA-type macroprolactin (macro-PRL) exists, though IgG-type macro-PRL is most common. This study clarifies the prevalence and characteristics of different macro-PRL types in patients.
Area of Science:
- Endocrinology
- Immunology
- Clinical Chemistry
Background:
- Macroprolactin (macro-PRL) is a complex of prolactin (PRL) with immunoglobulin G (IgG).
- The existence and prevalence of IgA-type macro-PRL have not been clearly defined.
Purpose of the Study:
- To determine if IgA-type macro-PRL exists.
- To investigate the prevalence of IgA-type macro-PRL compared to IgG-type.
- To analyze differences in laboratory data between macro-PRL types.
Main Methods:
- Analyzed 130 patients diagnosed with macroprolactinemia using polyethylene glycol precipitation and gel filtration chromatography (GFC).
- Identified IgA-type and IgG-type macro-PRLs using Jacalin column/SDS-PAGE and protein G columns.
- Utilized SDS-PAGE with IgA antibody and western blotting for identification.
Main Results:
- Confirmed the existence of IgA-type macro-PRL.
- Prevalence rates: 83.8% IgG-type, 7.7% IgA-type, 5.4% non-IgA/non-IgG, and 3.1% IgA plus IgG.
- No significant differences in PRL or macro-PRL ratios between IgA- and IgG-type macro-PRLs, but lower ratios in non-IgA/non-IgG type.
Conclusions:
- IgA-type macroprolactin has been demonstrated to exist.
- IgG-type macro-PRL is the most prevalent form.
- Prevalence order: IgG-type > IgA-type > non-IgA/non-IgG > IgA plus IgG.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

